{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:19:20Z","timestamp":1775161160740,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["107834\/Z\/15\/Z"],"award-info":[{"award-number":["107834\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106491\/Z\/14\/Z"],"award-info":[{"award-number":["106491\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000697","name":"Rhodes Scholarships","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New emerging infections have no known treatment. Assessing potential drugs for safety and efficacy enables clinicians to make evidence-based treatment decisions and contributes to overall outbreak control. However, it is difficult to launch clinical trials in the unpredictable environment of an outbreak. We conducted a bibliometric systematic review for the 2009 influenza pandemic to determine the speed and quality of evidence generation for treatments. This informs approaches to high-quality evidence generation in this and future pandemics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed for all clinical data (including clinical trial, observational and case series) describing treatment for patients with influenza A(H1N1)pdm09 and ClinicalTrials.gov for research that aimed to enrol patients with the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-three thousand eight hundred sixty-nine treatment courses for patients hospitalised with A(H1N1)pdm09 were detailed in 160 publications. Most were retrospective observational studies or case series. Five hundred ninety-two patients received treatment (or placebo) as participants in a registered interventional clinical trial with results publicly available. None of these registered trial results was available during the timeframe of the pandemic, and the median date of publication was 213\u2009days after the Public Health Emergency of International Concern ended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients were frequently treated for pandemic influenza with drugs not registered for this indication, but rarely under circumstances of high-quality data capture. The result was a reliance on use under compassionate circumstances, resulting in continued uncertainty regarding the potential benefits and harms of anti-viral treatment. Rapid scaling of clinical trials is critical for generating a quality evidence base during pandemics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-020-01732-5","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T06:22:35Z","timestamp":1597990955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-0756","authenticated-orcid":false,"given":"Amanda M.","family":"Rojek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Horby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"issue":"8","key":"1732_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"issue":"9979","key":"1732_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","volume":"385","author":"J Dobson","year":"2015","unstructured":"Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729\u201337.","journal-title":"Lancet."},{"issue":"2","key":"1732_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1056\/NEJMp0904380","volume":"361","author":"M Lipsitch","year":"2009","unstructured":"Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM. Managing and reducing uncertainty in an emerging influenza pandemic. N Engl J Med. 2009;361(2):112\u20135.","journal-title":"N Engl J Med"},{"key":"1732_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2334-14-32","volume":"14","author":"XL Wang","year":"2014","unstructured":"Wang XL, Wong CM, Chan KH, Chan KP, Cao PH, Peiris JM, et al. Hospitalization risk of the 2009 H1N1 pandemic cases in Hong Kong. BMC Infect Dis. 2014;14:32.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1732_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"2","key":"1732_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1378\/chest.12-2907","volume":"144","author":"IF Hung","year":"2013","unstructured":"Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464\u201373.","journal-title":"Chest."},{"issue":"2","key":"1732_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCM.0b013e3182a2727d","volume":"42","author":"CH Wang","year":"2014","unstructured":"Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014;42(2):313\u201321.","journal-title":"Crit Care Med"},{"key":"1732_CR8","doi-asserted-by":"publisher","first-page":"f3039","DOI":"10.1136\/bmj.f3039","volume":"346","author":"South East Asia Infectious Disease Clinical Research N","year":"2013","unstructured":"South East Asia Infectious Disease Clinical Research N. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013;346:f3039.","journal-title":"BMJ"},{"issue":"5","key":"1732_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/infdis\/jis765","volume":"207","author":"DW Kimberlin","year":"2013","unstructured":"Kimberlin DW, Acosta EP, Prichard MN, Sanchez PJ, Ampofo K, Lang D, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis. 2013;207(5):709\u201320.","journal-title":"J Infect Dis"},{"issue":"4","key":"1732_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3851\/IMP2680","volume":"19","author":"MG Ison","year":"2014","unstructured":"Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O\u2019Riordan W, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349\u201361.","journal-title":"Antivir Ther"},{"issue":"4","key":"1732_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/infdis\/jit467","volume":"209","author":"FM Marty","year":"2014","unstructured":"Marty FM, Man CY, van der Horst C, Francois B, Garot D, Manez R, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014;209(4):542\u201350.","journal-title":"J Infect Dis"},{"issue":"11","key":"1732_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/cid\/cit597","volume":"57","author":"N Lee","year":"2013","unstructured":"Lee N, Hui DS, Zuo Z, Ngai KL, Lui GC, Wo SK, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis. 2013;57(11):1511\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1732_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-016-0760-x","volume":"14","author":"AM Rojek","year":"2016","unstructured":"Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred research during epidemics. BMC Med. 2016;14(1):212.","journal-title":"BMC Med"},{"issue":"9681","key":"1732_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/S0140-6736(09)61131-4","volume":"373","author":"TH Tran","year":"2009","unstructured":"Tran TH, Ruiz-Palacios GM, Hayden FG, Farrar J. Patient-oriented pandemic influenza research. Lancet. 2009;373(9681):2085\u20136.","journal-title":"Lancet."},{"issue":"7","key":"1732_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1473-3099(14)70793-5","volume":"14","author":"FG Hayden","year":"2014","unstructured":"Hayden FG, Farrar J, Peiris JS. Towards improving clinical management of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2014;14(7):544\u20136.","journal-title":"Lancet Infect Dis"},{"key":"1732_CR16","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England J Med. 2020; [Epub ahead of print]."},{"key":"1732_CR17","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949 [Epub ahead of print].","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"1732_CR18","doi-asserted-by":"crossref","unstructured":"Rojek AM, Horby PW. Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections. Philos Trans R Soc Lond B Biol Sci. 2017;372(1721).","DOI":"10.1098\/rstb.2016.0294"},{"issue":"1","key":"1732_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62\u201370.","journal-title":"N Engl J Med"},{"key":"1732_CR20","doi-asserted-by":"crossref","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.","DOI":"10.1101\/2020.06.22.20137273"},{"key":"1732_CR21","unstructured":"The National Academies Press. Integrating clinical research into epidemic response: the Ebola experience. Washington, DC: The National Academies of Sciences, Engineering, Medicine; 2017."},{"key":"1732_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcrc.2017.02.009","volume":"40","author":"AH Rishu","year":"2017","unstructured":"Rishu AH, Marinoff N, Julien L, Dumitrascu M, Marten N, Eggertson S, et al. Time required to initiate outbreak and pandemic observational research. J Crit Care. 2017;40:7\u201310.","journal-title":"J Crit Care"},{"issue":"9","key":"1732_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/cid\/cix1061","volume":"66","author":"AM Rojek","year":"2018","unstructured":"Rojek AM, Dunning J, Leliogdowicz A, Castle L, Van Lieshout M, Carson G, et al. Regulatory and operational complexities of conducting a clinical treatment trial during an Ebola virus disease epidemic. Clin Infect Dis. 2018;66(9):1454\u20137.","journal-title":"Clin Infect Dis"},{"key":"1732_CR24","unstructured":"Wellcome Trust and The Academy of Medical Sciences. Use of neuraminidase inhibitors in influenza 2015. Available from: https:\/\/acmedsci.ac.uk\/file-download\/38069-561595082cd83.pdf. Accessed 29 Apr 2020."},{"issue":"9","key":"1732_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162199","volume":"11","author":"J Dunning","year":"2016","unstructured":"Dunning J, Kennedy SB, Antierens A, Whitehead J, Ciglenecki I, Carson G, et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS One. 2016;11(9):e0162199.","journal-title":"PLoS One"},{"issue":"2","key":"1732_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.antiviral.2013.08.016","volume":"100","author":"VC Cheng","year":"2013","unstructured":"Cheng VC, Chan JF, To KK, Yuen KY. Clinical management and infection control of SARS: lessons learned. Antivir Res. 2013;100(2):407\u201319.","journal-title":"Antivir Res"},{"issue":"11","key":"1732_CR27","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3201\/eid2511.180628","volume":"25","author":"ND Kayem","year":"2019","unstructured":"Kayem ND, Rojek A, Denis E, Salam A, Reis A, Olliaro P, et al. Clinical REsearch during outbreaks (CREDO) training for low- and middle-income countries. Emerg Infect Dis. 2019;25(11):2084\u20137.","journal-title":"Emerg Infect Dis"},{"key":"1732_CR28","doi-asserted-by":"crossref","unstructured":"Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827\u201335.","DOI":"10.1016\/S0140-6736(99)11433-8"},{"issue":"5","key":"1732_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000272","volume":"7","author":"W Xing","year":"2010","unstructured":"Xing W, Hejblum G, Leung GM, Valleron AJ. Anatomy of the epidemiological literature on the 2003 SARS outbreaks in Hong Kong and Toronto: a time-stratified review. PLoS Med. 2010;7(5):e1000272.","journal-title":"PLoS Med"},{"issue":"12","key":"1732_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028346","volume":"6","author":"JP Ioannidis","year":"2011","unstructured":"Ioannidis JP, Manzoli L, De Vito C, D'Addario M, Villari P. Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination. PLoS One. 2011;6(12):e28346.","journal-title":"PLoS One"},{"key":"1732_CR31","unstructured":"World Health Organisation. WHO Statement on Public Disclosure of Clinical Trial Results 2015 [Available from: https:\/\/www.who.int\/ictrp\/results\/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1. Accessed 29 Apr 2020."},{"issue":"4","key":"1732_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001819","volume":"12","author":"VS Moorthy","year":"2015","unstructured":"Moorthy VS, Karam G, Vannice KS, Kieny MP. Rationale for WHO\u2019s new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS Med. 2015;12(4):e1001819.","journal-title":"PLoS Med"},{"key":"1732_CR33","doi-asserted-by":"crossref","unstructured":"The Lancet Editorial Team. 10+ 10: rapid decisions and fast track publication for RCTs. Lancet. 2015;385(9968):578.","DOI":"10.1016\/S0140-6736(15)60218-5"},{"issue":"1","key":"1732_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40359-016-0167-7","volume":"4","author":"KS Button","year":"2016","unstructured":"Button KS, Bal L, Clark A, Shipley T. Preventing the ends from justifying the means: withholding results to address publication bias in peer-review. BMC Psychol. 2016;4(1):59.","journal-title":"BMC Psychol"},{"issue":"6481","key":"1732_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1126\/science.367.6481.963","volume":"367","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt K. Preprints bring \u2018firehose\u2019 of outbreak data. Science. 2020;367(6481):963\u20134.","journal-title":"Science."},{"issue":"7797","key":"1732_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/d41586-020-00613-4","volume":"579","author":"MA Johansson","year":"2020","unstructured":"Johansson MA, Saderi D. Open peer-review platform for COVID-19 preprints. Nature. 2020;579(7797):29.","journal-title":"Nature."},{"key":"1732_CR37","unstructured":"The MIT Press and UC Berkeley launch rapid reviews: COVID-19 2020 [updated June 29 2020]. Available from: https:\/\/rapidreviewscovid19.mitpress.mit.edu\/pub\/press-release."},{"issue":"6","key":"1732_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/QCO.0000000000000113","volume":"27","author":"M Zambon","year":"2014","unstructured":"Zambon M. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Curr Opin Infect Dis. 2014;27(6):560\u20135.","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"1732_CR39","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.292.11.1363","volume":"292","author":"CD DeAngelis","year":"2004","unstructured":"DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292(11):1363\u20134.","journal-title":"JAMA."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01732-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:14:51Z","timestamp":1629486891000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01732-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01732-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.07.20094839","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare one competing interest. We make the case for large-scale harmonised pandemic trials in this manuscript, and the senior author (Peter Horby) is leading the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which is the largest clinical trial for COVID-19 treatments presently enrolling across the UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}